CDER's Newest "Super-Office" Focuses On Drug Security
This article was originally published in The Pink Sheet Daily
Executive Summary
Reorganization of FDA Center for Drug Evaluation and Research's Office of Compliance includes a new entity dedicated to supply chain integrity, imports and recalls.
You may also be interested in...
CDER’s Drug Integrity Program Gains Formal Role In Compliance Office Reorg
FDA’s nascent Drug Integrity and Security Program gains an enhanced and more formal role with the reorganization and elevation of the Center for Drug Evaluation and Research’s Office of Compliance to “super-office” status.
CDER’s Drug Integrity Program Gains Formal Role In Compliance Office Reorg
FDA’s nascent Drug Integrity and Security Program gains an enhanced and more formal role with the reorganization and elevation of the Center for Drug Evaluation and Research’s Office of Compliance to “super-office” status.
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.